MyoPax is at the forefront of developing innovative therapies for muscle disorders, focusing on muscle regeneration through advanced cell and gene therapies. The company utilizes proprietary technologies to isolate and cultivate muscle stem cells, specifically Primary Human Satellite cells (PHSats), which retain their regenerative capabilities. This patented method allows for the production of high-purity populations of PHSats from minimal tissue samples, enabling effective autologous treatments for local muscle defects. Additionally, MyoPax is engineering hypo-immune PHSats derived from induced pluripotent stem cells (iPSCs) for allogeneic therapies, making these treatments more accessible and versatile.

The company also employs cutting-edge gene-editing technologies, particularly CRISPR/Cas, to repair mutations in genes associated with muscular dystrophies. This approach allows for precise and efficient correction of genetic defects, facilitating long-term muscle regeneration. MyoPax's therapeutic platforms, including Satori, Satuni, and Satgeno, target various muscle diseases through autologous and allogeneic strategies, showcasing their commitment to restoring muscle function and improving the quality of life for patients suffering from muscle impairments.

Germany

MyoPax uses its proprietary muscle stem cell technology to develop advanced regenerative therapies and fight the devastating consequences of muscle diseases.

MyoPax is a spin-off from Charité Universitätsmedizin and Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association.

MyoPax

Company Details